Summary: “The national rethink on psychedelic drugs is moving rapidly,” says The Boston Globe in an op-ed that covers the recent launch of the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital, which is affiliated with Harvard University. The launch of this center follows the establishment of similar psychedelic research centers at other prestigious institutions. The article also provides a short history of MAPS’ ongoing journey to FDA approval, outlining our clinical trials of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).
Originally appearing here.